NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.
You may also be interested in...
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.
UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities
The United Kingdom is creating a £600 million Cancer Drugs Fund to improve treatment access but a consultation document on the initiative is doing little to ease concerns about regional disparities in care.